Business Description
Rafael Holdings is a US-based holding company with investments in healthcare and real estate, focused primarily on developing treatments for cancer and rare genetic diseases. Its most advanced drug candidates include Trappsol Cyclo, targeting a rare and fatal genetic disorder called Niemann-Pick Disease Type C1, and devimistat, an anti-cancer compound, both currently in clinical trials. The company also has interests in surgical device development and owns commercial real estate holdings. Founded in 2017 and based in Newark, New Jersey, Rafael Holdings operates across both the United States and Israel.
